US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

60.94

-1.9700-3.13%

Pre-market: 61.160.2200+0.36%08:29 EDT

Volume:457.27K

Turnover:28.18M

Market Cap:2.93B

PE:-25.34

High:63.02

Open:62.43

Low:60.65

Close:62.91

52wk High:72.64

52wk Low:9.63

Shares:48.16M

Float Shares:27.63M

Volume Ratio:1.53

T/O Rate:1.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4052

EPS(LYR):-2.3824

ROE:-33.17%

ROA:-22.08%

PB:7.17

PE(LYR):-25.58

Loading ...

Overview Company News Filings

MBX Biosciences on Track for Record High Close

MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar

MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk

Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)

Shares of Mbx Biosciences Fall 9.9% After Cos Hormone Disorder Drug Data Fall Short of Expectations

THOMSON REUTERS

MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell

MT Newswires Live

BUZZ-MBX Biosciences reports one-year data for hormone disorder drug, shares fall

MBX Biosciences posts ENDO 2026 canvuparatide presentation update

MBX Biosciences announces results from Avail, canvuparatide trials

BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism

MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism

Mbx Biosciences - 90% of Patients in Ole Remained in Study at One Year

THOMSON REUTERS

Mbx Biosciences - Canvuparatide Well Tolerated With No New Safety Signals During One-Year Ole

THOMSON REUTERS

Mbx Biosciences - Responder Rate 57% at One Year Ole, 63% at 12 Weeks Phase 2 Avail Trial

THOMSON REUTERS

Mbx Biosciences - Phase 3 Pivotal Trial for Canvuparatide on Track to Initiate in Q3 2026

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)

Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)

MBX Biosciences Shareholders Approve Directors and Auditor

MBX Biosciences shareholders elect Patrick Heron, Edward Mathers as Class II directors

Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/MBX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":60.94,"timestamp":1789070400000,"preClose":62.91,"halted":0,"volume":457266,"hourTrading":{"tag":"盘前","latestPrice":61.16,"preClose":60.94,"latestTime":"08:29 EDT","volume":613,"amount":37323.769006,"timestamp":1789129791000,"change":0.22,"changeRate":0.00361,"amplitude":0.011323},"delay":0,"changeRate":-0.031314576378954045,"floatShares":27629899,"shares":48160096,"eps":-2.4052,"marketStatus":"Pre-Mkt","change":-1.97,"latestTime":"09-11 08:53:22 EDT","open":62.43,"high":63.015,"low":60.65,"amount":28182005.48331,"amplitude":0.037593,"askPrice":61.5,"askSize":100,"bidPrice":60.46,"bidSize":9,"shortable":3,"etf":0,"ttmEps":-2.4052,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789133400000},"marketStatusCode":1,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":60.94,"preHourTrading":{"tag":"盘前","latestPrice":61.16,"preClose":60.94,"latestTime":"08:29 EDT","volume":613,"amount":37323.769006,"timestamp":1789129791000,"change":0.22,"changeRate":0.00361,"amplitude":0.011323},"postHourTrading":{"tag":"盘后","latestPrice":60.94,"preClose":60.94,"latestTime":"19:30 EDT","volume":17579,"amount":1071329.49,"timestamp":1789083010061,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5256154305466962,"impliedVol":1.1078,"impliedVolPercentile":0.88},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":27629899,"roa":"-22.08%","roe":"-33.17%","lyrEps":-2.382369,"volumeRatio":1.5256154305466962,"shares":48160096,"dividePrice":0,"high":63.015,"amplitude":0.037593,"preClose":62.91,"low":60.65,"week52Low":9.63,"pbRate":"7.17","week52High":72.64,"institutionHeld":0,"latestPrice":60.94,"committee":-0.834862,"eps":-2.4052,"divideRate":0,"volume":457266,"delay":0,"ttmEps":-2.4052,"open":62.43,"prevYearClose":31.54,"prevWeekClose":61.72,"prevMonthClose":61.6,"prevQuarterClose":55.2,"fiveDayClose":60.89,"twentyDayClose":66.97,"sixtyDayClose":38.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"MBX","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2026-05-07","symbol":"MBX","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2026-03-12","symbol":"MBX","fiscalQuarterEnding":"2025/12","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1787371200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-09-10","current":-25.33677,"percent":0.088176,"low":-38.854907,"twenty":-19.254278,"median":-13.751441,"eighty":-5.782152,"high":-3.125337,"avg":-13.927577,"sd":8.346501,"marketCap":3029751639},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-06","current":-20.109671,"twenty":-15.97998,"median":-7.994552,"eighty":-5.365916,"marketCap":1618727987},{"date":"2026-02-13","current":-22.260078,"twenty":-16.085028,"median":-8.265761,"eighty":-5.405044,"marketCap":1791824944},{"date":"2026-02-20","current":-21.826592,"twenty":-16.300015,"median":-8.354645,"eighty":-5.422333,"marketCap":1756931510},{"date":"2026-02-27","current":-20.526135,"twenty":-16.365085,"median":-8.65641,"eighty":-5.437203,"marketCap":1652251211},{"date":"2026-03-06","current":-18.414356,"twenty":-16.656674,"median":-8.777334,"eighty":-5.439664,"marketCap":1482263608},{"date":"2026-03-13","current":-15.268438,"twenty":-16.663558,"median":-8.888641,"eighty":-5.448143,"marketCap":1327911291},{"date":"2026-03-20","current":-15.530651,"twenty":-16.662191,"median":-9.207959,"eighty":-5.4632,"marketCap":1350716208},{"date":"2026-03-27","current":-15.454172,"twenty":-16.656674,"median":-9.44019,"eighty":-5.477809,"marketCap":1344064774},{"date":"2026-04-02","current":-17.639279,"twenty":-16.656721,"median":-9.686541,"eighty":-5.527885,"marketCap":1534105746},{"date":"2026-04-10","current":-17.950657,"twenty":-16.797941,"median":-9.847355,"eighty":-5.527885,"marketCap":1561186584},{"date":"2026-04-17","current":-18.147317,"twenty":-16.939398,"median":-9.944254,"eighty":-5.546084,"marketCap":1578290272},{"date":"2026-04-24","current":-18.240184,"twenty":-16.993812,"median":-10.091627,"eighty":-5.548359,"marketCap":1586367013},{"date":"2026-05-01","current":-16.529418,"twenty":-17.017199,"median":-10.162452,"eighty":-5.565633,"marketCap":1437580056},{"date":"2026-05-08","current":-19.051466,"twenty":-17.024271,"median":-10.419594,"eighty":-5.573382,"marketCap":1651171534},{"date":"2026-05-15","current":-19.432949,"twenty":-17.098465,"median":-10.797864,"eighty":-5.623429,"marketCap":1683048872},{"date":"2026-05-22","current":-17.470969,"twenty":-17.116218,"median":-10.949581,"eighty":-5.635398,"marketCap":1513125669},{"date":"2026-05-29","current":-17.531422,"twenty":-17.244113,"median":-11.182744,"eighty":-5.640382,"marketCap":1518361398},{"date":"2026-06-05","current":-16.987343,"twenty":-17.244113,"median":-11.332873,"eighty":-5.647113,"marketCap":1471239837},{"date":"2026-06-12","current":-20.471645,"twenty":-17.244113,"median":-11.549143,"eighty":-5.650278,"marketCap":1773008216},{"date":"2026-06-18","current":-22.856798,"twenty":-17.305607,"median":-11.667238,"eighty":-5.653457,"marketCap":1979581522},{"date":"2026-06-26","current":-27.68206,"twenty":-17.435508,"median":-11.803503,"eighty":-5.659497,"marketCap":2397487888},{"date":"2026-07-02","current":-30.732198,"twenty":-17.480357,"median":-11.965702,"eighty":-5.666777,"marketCap":2661654213},{"date":"2026-07-10","current":-36.112531,"twenty":-17.527026,"median":-11.991245,"eighty":-5.673476,"marketCap":3127634090},{"date":"2026-07-17","current":-32.051177,"twenty":-17.634503,"median":-12.154761,"eighty":-5.678788,"marketCap":2775888299},{"date":"2026-07-24","current":-34.936442,"twenty":-17.867538,"median":-12.324334,"eighty":-5.688724,"marketCap":3025775363},{"date":"2026-07-31","current":-36.524712,"twenty":-17.911832,"median":-12.436374,"eighty":-5.691675,"marketCap":3163332242},{"date":"2026-08-07","current":-30.628146,"twenty":-17.994359,"median":-12.627144,"eighty":-5.692585,"marketCap":3194270640},{"date":"2026-08-14","current":-30.97629,"twenty":-18.158049,"median":-12.72465,"eighty":-5.698044,"marketCap":3230579239},{"date":"2026-08-21","current":-30.63919,"twenty":-18.368939,"median":-13.111638,"eighty":-5.710784,"marketCap":3195422369},{"date":"2026-08-28","current":-30.657661,"twenty":-18.452139,"median":-13.429759,"eighty":-5.738476,"marketCap":3197348773},{"date":"2026-09-04","current":-28.362608,"twenty":-19.064304,"median":-13.72255,"eighty":-5.766956,"marketCap":2957993096},{"date":"2026-09-10","current":-29.050662,"twenty":-19.254278,"median":-13.751441,"eighty":-5.782152,"marketCap":3029751639}],"updateTime":1789131202867},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649794620","title":"MBX Biosciences on Track for Record High Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2649794620","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649794620?lang=en_us&edition=fundamental","pubTime":"2026-07-06 23:21","pubTimestamp":1783351260,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc.  is currently at $59.18, up $1.38 or 2.38%--Would be new all-time closing high --On pace for largest percent increase since July 2, 2026, when it rose 3.36%--Currently up 17 of the past 18 days--Currently up 14 consecutive days; up 66.64% over this period--Longest winning streak on record --Best 14 day stretch since the 14 days ending Nov. 11, 2025, when it rose 68.54%--Up 87.62% year-to-date--Up 359.43% from 52 weeks ago , when it closed at $12.88--Would be a new 52-week closing high--Up 507.23% from its 52-week closing low of $9.75 on Sept. 16, 2025--Traded as high as $59.38; new all-time intraday high --Up 2.73% at today's intraday highAll data as of 11:16:26 AM ETSource: Dow Jones Market Data, FactSet Dow Jones NewswiresJuly 06, 2026 11:21 ET Copyright  2026 Dow Jones & Company, Inc.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648568468","title":"MBX Biosciences Completes STEADI Trial, Putting Imapextide on Investors’ Radar","url":"https://stock-news.laohu8.com/highlight/detail?id=2648568468","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648568468?lang=en_us&edition=fundamental","pubTime":"2026-07-03 00:31","pubTimestamp":1783009864,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ($MBX) announced an update on their ongoing clinical study. MBX Biosciences, Inc. is running the STEADI Phase 2a study to tes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-completes-steadi-trial-putting-imapextide-on-investors-radar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-completes-steadi-trial-putting-imapextide-on-investors-radar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ISBC","MBX","BK4211","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643529266","title":"MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2643529266","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643529266?lang=en_us&edition=fundamental","pubTime":"2026-06-13 01:21","pubTimestamp":1781284860,"startTime":"0","endTime":"0","summary":"Copyright (c) 2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4585","ISBC","BK4211","LU0320765992.SGD","ASND","LU0109394709.USD","MBX","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643294455","title":"Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643294455","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643294455?lang=en_us&edition=fundamental","pubTime":"2026-06-13 00:30","pubTimestamp":1781281817,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MBX Biosciences, Inc. (MBX) and Kura Oncology (KURA)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-mbx-biosciences-inc-mbx-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-mbx-biosciences-inc-mbx-kura-oncology-kura-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LABU","BK4585","HCSG","BK4581","LU0128526141.USD","XLV","BK4588","BK4007","LU0029874061.USD","BK4137","KURA","XBI","MBX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642510299","title":"Shares of Mbx Biosciences Fall 9.9% After Cos Hormone Disorder Drug Data Fall Short of Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2642510299","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642510299?lang=en_us&edition=fundamental","pubTime":"2026-06-12 22:39","pubTimestamp":1781275156,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL4N42K13V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260446","title":"MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260446","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260446?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:54","pubTimestamp":1781265299,"startTime":"0","endTime":"0","summary":"MBX Biosciences  said Friday that the Avail phase 2 trial of once-weekly canvuparatide to treat chronic hypoparathyroidism met its primary composite endpoint at 12 weeks.The primary endpoint required patients to normalize their serum calcium levels while eliminating the need for active vitamin D and reducing daily calcium supplements to less than 600 mg.The company also released new one-year open-label extension data showing a 57% responder rate, with 90% of the entering patients continuing the treatment.The treatment demonstrated solid initial retention, with 60 patients advancing into the two-year open-label extension after the core 12-week trial.The company remains on track to begin the phase 3 trial in Q3 2026.Shares of MBX Biosciences were down more than 16% pre-bell after surging 20% in Thursday's trading session.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642603722","title":"BUZZ-MBX Biosciences reports one-year data for hormone disorder drug, shares fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2642603722","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642603722?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:35","pubTimestamp":1781264117,"startTime":"0","endTime":"0","summary":"BUZZ-MBX Biosciences reports one-year data for hormone disorder drug, shares fall** Shares of drug developer MBX Biosciences MBX.O fall 8.7% to $34 premarket** MBX says its experimental once-weekly drug, canvuparatide, showed sustained benefit in patients with chronic hypoparathyroidism, a hormone disorder that causes low calcium levels** In a one-year open-label extension study, 57% of patients met the main response criteria, compared with 63% response rate seen at 12 weeks in a mid-stage trial** Investors were hoping to see a continuation of the 79% response rate seen at six months data, Barclays says** Injection site reactions were reported in 10% of patients in the open-label extension study - MBX** Company says it remains on track to start a late-stage trial in Q3 2026** Up to last close, shares up 18% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nL4N42K0SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267130","title":"MBX Biosciences posts ENDO 2026 canvuparatide presentation update","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267130?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:12","pubTimestamp":1781262756,"startTime":"0","endTime":"0","summary":"Phase 2 results were described as positive, with Phase 3 initiation targeted for Q3 2026.The presentation framed chronic hypoparathyroidism as affecting more than 250,000 patients across the US and EU.Study design details included a 12-week Phase 2 trial with a 2-year open-label extension tracking responder rates, urine calcium, bone markers, and immunogenicity.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDLdFhrS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642279267","title":"MBX Biosciences announces results from Avail, canvuparatide trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2642279267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642279267?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:10","pubTimestamp":1781262608,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) announced full results from the 12-week Avail Phase 2 trial and new one-year data from the ongoing open-label extension study...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-announces-results-from-avail-canvuparatide-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-announces-results-from-avail-canvuparatide-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642507267","title":"BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2642507267","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642507267?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:03","pubTimestamp":1781262229,"startTime":"0","endTime":"0","summary":"BRIEF-Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic HypoparathyroidismJune 12 (Reuters) - MBX B","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA85PQ05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642826732","title":"MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2642826732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642826732?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262029,"startTime":"0","endTime":"0","summary":"MBX Biosciences says Phase 2 data show once-weekly canvuparatide sustains 57% responder rate at one year in hypoparathyroidism. Data showed sustained disease control over a year, supporting physiologic PTH replacement with reduced reliance on standard supplements.Kidney function and bone activity trends stayed consistent with restored PTH action, reinforcing the broader clinical profile beyond calcium control.Safety remained generally favorable over a year, with no new safety signals reported during the extension period.One-year extension results were set for presentation June 12 at ENDO 2026; full 12-week Phase 2 results were scheduled for June 13.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL5DH25m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","SG9999014039.USD","SG9999014013.SGD","IE00BN0W2W23.USD","BK4112","SG9999014005.SGD","LU2210149790.SGD","MBX","NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642675532","title":"Mbx Biosciences - 90% of Patients in Ole Remained in Study at One Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2642675532","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642675532?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA85PQ05:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642673632","title":"Mbx Biosciences - Canvuparatide Well Tolerated With No New Safety Signals During One-Year Ole","url":"https://stock-news.laohu8.com/highlight/detail?id=2642673632","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642673632?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA85PQ05:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642326738","title":"Mbx Biosciences - Responder Rate 57% at One Year Ole, 63% at 12 Weeks Phase 2 Avail Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2642326738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642326738?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA85PQ05:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642267387","title":"Mbx Biosciences - Phase 3 Pivotal Trial for Canvuparatide on Track to Initiate in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642267387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642267387?lang=en_us&edition=fundamental","pubTime":"2026-06-12 19:00","pubTimestamp":1781262001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nTUA85PQ05:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642444723","title":"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) and GoodRx Holdings (GDRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642444723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642444723?lang=en_us&edition=fundamental","pubTime":"2026-06-10 17:20","pubTimestamp":1781083235,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY), MBX Biosciences, Inc. (MBX) ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-mbx-biosciences-inc-mbx-and-goodrx-holdings-gdrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-mbx-biosciences-inc-mbx-and-goodrx-holdings-gdrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0820561818.USD","IE00B775H168.HKD","LU2417539215.USD","SG9999001176.USD","LU0234572021.USD","SGXZ81514606.USD","LU1974910355.USD","LU1064131342.USD","LU1551013425.SGD","LU1291159041.SGD","LU0882574055.USD","LU1629891620.HKD","SGXZ51526630.SGD","LU2213496289.HKD","LU0385154629.USD","LU0114720955.EUR","LU2087625088.SGD","LU2456880835.USD","LU1868837136.USD","LU0210536198.USD","BK4516","LU1023059063.AUD","LU1366192091.USD","LU2237443895.HKD","LU1720051017.SGD","LU2211815571.USD","BK4533","LU2746668461.USD","LU2471134879.HKD","LU0109391861.USD","LU0203201768.USD","IE00B7KXQ091.USD","SG9999018865.SGD","LU2471134796.USD","LU0823434583.USD","LU1868836914.USD","SG9999015945.SGD","LU1868837300.USD","LU2023250504.SGD","IE00BKDWB100.SGD","LU0882574139.USD","LU2361044949.HKD","LU2471134523.USD","BK4167","LU0266013472.USD","LU0289739699.SGD","IE00BK4W5L77.USD","LU0417517546.SGD","LU2602419157.SGD","IE00B4R5TH58.HKD","SGXZ31699556.SGD","SGXZ57979304.SGD","LU0158827781.USD","LU0097036916.USD","LU1057294990.SGD","LU0964807845.USD","BK4534","LU0353189680.USD","LU2271345857.HKD","LLY","LU0079474960.USD","LU0158827948.USD","LU1061106388.HKD","LU1267930730.SGD","LU1720051108.HKD","LU0198837287.USD","LU2168564222.USD","LU1983299246.USD","LU0096364046.USD","LU2089283258.USD","LU2089284900.SGD","LU2265009873.SGD","LU2756315664.SGD","LU0672654240.SGD","LU1232071149.USD","LU0432979614.USD","LU2750360641.GBP","LU1551013342.USD","LU0786609619.USD","LU0320765059.SGD","IE0001KFT4U8.USD","IE00B1XK9C88.USD","BK4581","LU2111349929.HKD","IE00BJJMRZ35.SGD","LU1145028129.USD","LU2168564149.EUR","LU2236285917.USD","LU2237443465.HKD","LU2237443549.SGD","LU2552382058.USD","LU0058720904.USD","LU0943347566.SGD","IE00BN29S564.USD","LU0354030511.USD","BK4588","SG9999015978.USD","LU0820561909.HKD","LU0471298777.SGD","LU2462157665.USD","IE0004445239.USD","LU0820562030.AUD","LU2896262040.SGD","LU2108987350.USD","LU1623119135.USD","ELIL","LU0323591593.USD","LU2360106947.USD","LU2471134952.CNY","LU2112291526.USD","LU2237443622.USD","IE00BJJMRX11.SGD","LU0094547139.USD","LU2237443978.SGD","IE00B4JS1V06.HKD","LU0689472784.USD","LU0061475181.USD","LU0640476718.USD","LU2324357040.USD","SG9999017495.SGD","SG9999018857.SGD","LU1093756325.SGD","LU2756315318.SGD","SG9999014906.USD","LU0006306889.USD","LU2106854487.HKD","BK4599","LU2168563687.JPY","IE00BFTCPJ56.SGD","LU0354030438.USD","LU1323610961.USD","IE00BFSS8Q28.SGD","LU1280957306.USD","LU1989771016.USD","LU0889565916.HKD","LU0466842654.USD","LU0109394709.USD","LU2468319806.SGD","IE0002141913.USD","SGXZ99366536.SGD","LU1804176565.USD","LU0683600562.USD","LU1712237335.SGD","LU2063271972.USD","LU1035775433.USD","IE00BJLML261.HKD","LU2237443382.USD","BK4007","LU2361045086.USD","LU0238689110.USD","LU2168564065.EUR","LLYX","LU2750360997.AUD","LU1868836591.USD","IE0005OL40V9.USD","LU2491049909.HKD","LU1814569148.SGD","LU2168564495.EUR","LU2023251221.USD","MBX","LU2028103732.USD","LU2023250330.USD","LU2089984988.USD","LU2491050071.SGD","IE00B1BXHZ80.USD","LU0471298694.HKD","SG9999014914.USD","LU2237438978.USD","SG9999001176.SGD","ELIS","LU0256863902.USD","LU0353189763.USD","LU1868836757.USD","IE00BJJMRY28.SGD","LU1093756168.USD","LU0823434740.USD","LU2264538146.SGD","LU2361044865.SGD","LU0320765992.SGD","IE00BFSS7M15.SGD","LU1069344957.HKD","IE0009355771.USD","SG9999014898.SGD","LLII","LU2746668974.SGD","IE00B2B36J28.USD","IE00BK4W5M84.HKD","LU0316494557.USD","LU0708995401.HKD","SG9999015986.USD","LU1548497426.USD","IE0004445015.USD","LU0203202063.USD","IE00BJT1NW94.SGD","LU0133085943.USD","LU2552382215.SGD","LU0256863811.USD","LU2461242641.AUD","SG9999014880.SGD","LU0456855351.SGD","LU0787776722.HKD","IE00BKPKM429.USD","LU0225283273.USD","LU2357305700.SGD","SG9999015952.SGD","LU0106261372.USD","BK4585","GDRX","LU2491050154.USD","LU1917777945.USD","IE00BWXC8680.SGD","LLYZ","LU0823416689.USD","LU1988902786.USD","LU0122379950.USD","GB00BDT5M118.USD","LU1127390331.HKD","SG9999013999.USD","LU2552382132.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642058433","title":"Analysts Offer Insights on Healthcare Companies: Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immunotherapeutics (MLTX) and MBX Biosciences, Inc. (MBX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642058433","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642058433?lang=en_us&edition=fundamental","pubTime":"2026-06-09 00:40","pubTimestamp":1780936810,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Artiva Biotherapeutics, Inc. (ARTV), MoonLake Immuno...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-artiva-biotherapeutics-inc-artv-moonlake-immunotherapeutics-mltx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-artiva-biotherapeutics-inc-artv-moonlake-immunotherapeutics-mltx-and-mbx-biosciences-inc-mbx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4581","ARTV","BK4588","XBI","BK4139","MBX","BK4137","MLTX","XLV","LU0128526141.USD","HCSG","LU0029874061.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641110760","title":"MBX Biosciences Shareholders Approve Directors and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2641110760","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641110760?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:17","pubTimestamp":1780661877,"startTime":"0","endTime":"0","summary":"An update from MBX Biosciences, Inc. ( ($MBX) ) is now available. MBX Biosciences, Inc., a publicly traded biopharmaceutical company with 47,570,48...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-shareholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-shareholders-approve-directors-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641108751","title":"MBX Biosciences shareholders elect Patrick Heron, Edward Mathers as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641108751","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641108751?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:53","pubTimestamp":1780660398,"startTime":"0","endTime":"0","summary":"MBX Biosciences held its annual shareholder meeting on June 4, 2026.Shareholders also backed the board’s two Class II director nominees for three-year terms ending at the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLQGlL7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641197516","title":"Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641197516","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641197516?lang=en_us&edition=fundamental","pubTime":"2026-06-05 13:31","pubTimestamp":1780637485,"startTime":"0","endTime":"0","summary":"MBX Biosciences recently outlined its participation at the Jefferies Global Healthcare Conference in New York and scheduled a June 12, 2026 investor webcast and call to discuss new once-weekly canvuparatide data from ENDO 2026, including one-year open-label extension and full 12-week Phase 2 Avail trial results.\nThese upcoming endocrinology-focused presentations highlight canvuparatide’s central role in MBX Biosciences’ pipeline and could refine how investors assess the company’s clinical...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/should-upcoming-canvuparatide-phase-2-data-presentations-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/should-upcoming-canvuparatide-phase-2-data-presentations-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4007","BK4211","MBX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":106,"code":"91000000","status":"200"}]}}